We are live on ! Find out more
NLG

New Legacy Group Portfolio holdings

AUM $36.6M
1-Year Est. Return 36.77%
This Fund
S&P 500
This Quarter Est. Return
+3.18%
1 Year Est. Return
+36.77%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$38.8M
AUM Growth
-$10.5M
Cap. Flow
-$14.3M
Cap. Flow %
-36.84%
Top 10 Hldgs %
80.15%
Holding
28
New
–
Increased
–
Reduced
3
Closed
1

Top Buys

No buys this quarter

Top Sells

Rank Stock Value
1
RIVN icon
Rivian
RIVN
+$13.9M
2
AAPL icon
Apple
AAPL
+$188K
3
PHAS
PhaseBio Pharmaceuticals, Inc. Common Stock
PHAS
+$144K
4
GVI icon
iShares Intermediate Government/Credit Bond ETF
GVI
+$63K

Sector Composition

Rank Sector Weight
1 Consumer Discretionary 23.48%
2 Communication Services 10.69%
3 Technology 7.21%
4 Healthcare 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
IYC icon
26
iShares US Consumer Discretionary ETF
IYC
$1.12B
$244K 0.63%
4,200
– –
XBI icon
27
State Street SPDR S&P Biotech ETF
XBI
$10.1B
$222K 0.57%
2,805
– –
PHAS
28
DELISTED
PhaseBio Pharmaceuticals, Inc. Common Stock
PHAS
– –
-240,575
Closed -$144K
1
2

Similar funds

BEVI
Braemar Energy Ventures III New York $37.9M AUM 66.45% 1-Year Est. Return
BGDR
BC Gestao de Recursos Sao Paulo, Brazil $38.2M AUM
ZAM
Zeal Asset Management Central, Hong Kong $39.4M AUM 38.83% 1-Year Est. Return
HCM
Hawkeye Capital Management Miami Beach, Florida $40.6M AUM 11.3% 1-Year Est. Return
MAM
Must Asset Management Seoul, South Korea $40.9M AUM 22.53% 1-Year Est. Return
QI
Qualcomm Inc San Diego, California $32.1M AUM 5.35% 1-Year Est. Return
AC
Amia Capital London, United Kingdom $32.1M AUM 0.56% 1-Year Est. Return
SAM
Sandbar Asset Management London, United Kingdom $30.5M AUM 46.07% 1-Year Est. Return

New Legacy Group's Q3 2022 Portfolio in Review

As of Q3 2022, New Legacy Group held 28 positions worth $38.8M, down 21% from $49.3M the previous quarter. Its ten largest holdings account for 80% of the portfolio.

New Legacy Group withdrew a net $14.3M in Q3 2022, closing 1 position and reducing 3 holdings. Its most notable exit was PhaseBio Pharmaceuticals, Inc. Common Stock, an estimated $144K position sold in full.

By sector, the portfolio is most concentrated in Consumer Discretionary at 23% of assets, down from 36% a quarter earlier, followed by Communication Services and Technology.

  • New Legacy Group's biggest Q3 2022 reduction was Rivian, cutting an estimated $13.9M.
  • New Legacy Group fully exited PhaseBio Pharmaceuticals, Inc. Common Stock in Q3 2022, selling an estimated $144K.
  • New Legacy Group's ten largest holdings make up 80% of its $38.8M portfolio in Q3 2022.
  • New Legacy Group opened 0 new positions and closed 1 in Q3 2022.
  • New Legacy Group's portfolio value fell 21% quarter-over-quarter to $38.8M.

Based on New Legacy Group's 13F filing for Q3 2022, filed 14 Nov 2022.